Boehringer Ingelheim ties the knot with Numab on new antibodies; Cabaletta inks pact with Artisan
→ Switzerland’s Numab Therapeutics has added Boehringer Ingelheim to its roster of collaborators. And they will start with two projects aiming at developing new drugs for difficult-to-treat lung and gastrointestinal cancers and patients with geographic atrophy. “Numab’s technology platform fits well with our internal antibody discovery and engineering capabilities and will enhance our efforts to deliver transformative antibody-based therapeutics to patients,” said Paige Mahaney, an SVP at Boehringer Ingelheim.
→ Cabaletta Bio and Artisan Bio, a precision cell therapy engineering company, have signed a research and collaboration agreement to “accelerate development of next-generation CAAR T cell therapies for patients with B cell-mediated autoimmune diseases.”
→ Neurogene reports that the FDA granted an orphan drug designation to their gene therapy, an adeno-associated virus vector with engineered transgene encoding the human CLN5 gene for patients with CLN5, a form of Batten disease.